PEOPLE - diaDexus (US) makes appointment:
This article was originally published in Clinica
diaDexus, the US diagnostics joint venture between SmithKline Beecham and Incyte Pharmaceuticals, has named Dr George Poste acting CEO. Dr Poste, who replaces Dr William Gerber, will continue in his current role as diaDexus' chairman and SmithKline Beecham's chief science and technology officer.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.